- Home
- CTW vs MEIP Comparison
CTW vs MEIP Comparison
Compare CTW & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTW
- MEIP
- Stock Information
- Founded
- CTW 2013
- MEIP 2000
- Country
- CTW Japan
- MEIP United States
- Employees
- CTW N/A
- MEIP N/A
- Industry
- CTW EDP Services
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- CTW Technology
- MEIP Health Care
- Exchange
- CTW Nasdaq
- MEIP Nasdaq
- Market Cap
- CTW 171.4M
- MEIP 153.9M
- IPO Year
- CTW 2025
- MEIP 2003
- Fundamental
- Price
- CTW $1.87
- MEIP $4.83
- Analyst Decision
- CTW
- MEIP
- Analyst Count
- CTW 0
- MEIP 0
- Target Price
- CTW N/A
- MEIP N/A
- AVG Volume (30 Days)
- CTW 924.2K
- MEIP 3.2M
- Earning Date
- CTW 01-01-0001
- MEIP 09-18-2025
- Dividend Yield
- CTW N/A
- MEIP N/A
- EPS Growth
- CTW N/A
- MEIP N/A
- EPS
- CTW N/A
- MEIP N/A
- Revenue
- CTW $76,194,020.00
- MEIP N/A
- Revenue This Year
- CTW N/A
- MEIP N/A
- Revenue Next Year
- CTW N/A
- MEIP N/A
- P/E Ratio
- CTW $44.00
- MEIP N/A
- Revenue Growth
- CTW 8.71
- MEIP 33.76
- 52 Week Low
- CTW $1.84
- MEIP $1.46
- 52 Week High
- CTW $4.88
- MEIP $9.00
- Technical
- Relative Strength Index (RSI)
- CTW N/A
- MEIP 52.49
- Support Level
- CTW N/A
- MEIP $4.81
- Resistance Level
- CTW N/A
- MEIP $5.39
- Average True Range (ATR)
- CTW 0.00
- MEIP 0.59
- MACD
- CTW 0.00
- MEIP -0.18
- Stochastic Oscillator
- CTW 0.00
- MEIP 7.14
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.